Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106077 · ClinicalTrials.gov registry record · Phase 2
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT03106077: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03106077 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03106077, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer. Drugs used in chemotherapy, such as mirvetuximab soravtansine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- BIOLOGICAL Mirvetuximab Soravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03106077
The ClinicalTrials.gov registry entry for NCT03106077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirvetuximab Soravtansine is the first listed.
NCT03106077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03106077 about?
NCT03106077 is a clinical study titled "Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer". This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer. Drugs used in chemotherapy, such as mirvetuximab soravtansine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stoppin...
What is the current status of trial NCT03106077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2017-06-05. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03106077?
The interventions under investigation include: Mirvetuximab Soravtansine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03106077?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.